Lushang Freda Pharmaceutical Co.,Ltd. (SHA:600223)
China · Delayed Price · Currency is CNY 5.58
-0.06 (-1.06%)
Jun 9, 2026, 3:00 PM CST
SHA:600223 Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, SHA:600223 stock has a consensus rating of "Strong Buy" and an average price target of ¥8.25. The average 1-year stock price forecast is 47.85% higher than the current stock price, while the lowest is ¥8.20 (+46.95%) and the highest is ¥8.30 (+48.75%).
Price Target: ¥8.25 (+47.85%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SHA:600223 stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 4 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 5 | 4 | 3 | 3 |
Financial Forecast
Revenue This Year
3.93B
from 3.65B
Increased by 7.75%
Revenue Next Year
4.29B
from 3.93B
Increased by 9.01%
EPS This Year
0.25
from 0.17
Increased by 47.06%
EPS Next Year
0.28
from 0.25
Increased by 12.00%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.0B | ||
| Avg | 3.9B | ||
| Low | 3.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 10.8% | ||
| Avg | 7.7% | ||
| Low | 4.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 0.25 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 47.1% | ||
| Low | - |